Peptide
PACAP
SavePituitary Adenylate Cyclase-Activating Polypeptide, a pleiotropic neuropeptide with roles in neuroprotection, vasodilation, immune modulation, and migraine pathophysiology.
Quick verdict
Important research neuropeptide linked to migraine and neuroprotection. PACAP receptor antagonists are under clinical development for migraine, but PACAP itself is not used therapeutically.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
PACAP infusion triggers migraine in susceptible individuals, validating it as a target. PACAP receptor (PAC1) antagonists are in clinical trials. Neuroprotective effects are preclinical.
Benefits
- Validates migraine pathophysiology research
- Neuroprotective effects in preclinical stroke models
- Important target for next-generation migraine therapies
Dosage notes
Research use: IV infusion at pmol/kg/min. Not a therapeutic peptide for self-administration.
Side effects
- Migraine induction
- Flushing
- Hypotension
- Palpitations
Who should be cautious
Exogenous PACAP administration causes migraine, flushing, and hypotension. Not suitable as a general therapeutic.
What this page cannot tell you
Value is primarily as a research tool and drug target, not as an exogenous therapeutic agent.
Leaderboard scores
- Pain15
- Stress15
Write a review
Sign in to write a review.